Effective September 8, 2012, Pernix Therapeutics Holdings, Inc., a Maryland corporation (the "Company"), entered into the First Amendment to Loan Agreement (the "First Amendment"), which amended that certain Loan Agreement, effective as of September 8, 2010, by and among the Company and Pernix Therapeutics, LLC, as Borrowers, and Regions Bank, as the Lender (the "Loan Agreement"). The First Amendment extended the maturity of the Loan Agreement from September 8, 2012 to December 31, 2012. There were no other changes to the Loan Agreement.

The description set forth above is qualified in its entirety by reference to the First Amendment, which is filed hereto as Exhibit 10.1 and is incorporated herein by reference.

The information set forth under Item 1.01 of this Current Report on Form 8-K is hereby incorporated in this Item 2.03 by reference.

If an event of default occurs and is continuing, on the terms and subject to the conditions set forth in the Loan Agreement, as amended, amounts outstanding under the Loan Agreement, as amended, may be accelerated and may become or be declared immediately due and payable.

(d) Exhibits.

Exhibit
Number      Description

  10.1      First Amendment to Loan Agreement effective as of
            September 8, 2012 by and among Pernix Therapeutics
            Holdings, Inc. and Pernix Therapeutics, LLC, as
            Borrowers, and Regions Bank, as Lender.